RetroSense Therapuetics Logowhite spacerGo to about RetroSenseGo to Investors and Partners pageGo to Product DevelopmentGo to Therapeutics AreasGo to Frequently Asked QuestionsGo to Contact Page
left image bandRight Image band
photoRetroSense Therapeutics develops game-changing gene therapy solutions to restore partial sight for certain eye diseases.

To find out more about RetroSense Therapeutics, please click through to the Contact Us page. We are currently seeking accredited financial partners and strategic partners interested in collaborating with us to develop our lead candidate.
 


Visit us on facebook.
Link to FaceBook


 

 

 

 

 

 

 

 

 

RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.

The RetroSense gene therapy technology has been demonstrated to confer light sensitivity to retinal nerve cells and restore functional vision in animal studies. Our lead product candidate, RST-001, will be developed initially for RP with advanced dry-AMD as a follow-on indication. RST-001 is not currently in human clinical trials. Please visit us periodically to see how we are making progress in vision restoration.